Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib plus abiraterone for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer
jRCT2080225302Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in prostate adenocarcinoma and prostate cancer (PCa) comparing Capivasertib + abiraterone with Placebo + abiraterone (2 arms). Started Aug 2020; status: completed.
02
Drugs
capivasertibabiraterone
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080225302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225302.